| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to tre... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical facts, contained in this presentation, including statements about our expectat... |
| 17 Jul 2026 |
8-K: Other Events
We have acted as counsel to Tvardi Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company of shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate... |
| 07 Jul 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical facts, contained in this presentation, including statements about our expectat... |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Tvardi Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the four proposals set forth below. A more detailed des... |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update |
| 06 Mar 2026 |
8-K: Other Events
Tvardi Therapeutics, Inc. (the “Company”) has set June 9, 2026 as the date for the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Proposals of stockholders intended to be presented at the 2026 Annual Meeting p... |
| 16 Jan 2026 |
8-K: Regulation FD Disclosure
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our expectation... |
| 18 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 16, 2025, the Board of Directors of Tvardi Therapeutics, Inc. (the “Company”) approved one-time retention compensation for certain of the Company’s employees, as recommended by the Compensation Committee of the Board, includi... |
| 19 Nov 2025 |
8-K: Regulation FD Disclosure
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our expectation... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026 |
| 14 Oct 2025 |
8-K: Other Events
Tvardi Therapeutics Provides Update on Preliminary Data from |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025 |
| 14 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 8, 2025, Shaheen Wirk resigned as a member of the Board of Directors (the “Board”) of Tvardi Therapeutics, Inc. (the “Company”). Dr. Wirk’s decision to resign from the Board was not the result of any disagreement with the Company... |
| 09 Jun 2025 |
8-K: Other Events
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our expectation... |
| 27 May 2025 |
8-K: Regulation FD Disclosure
Topline data from the REVERTIPF trial anticipated in 4Q 2025 |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition; Changes in Registrant's Certifying Accountant
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update |
| 15 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +8 more
(a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any ... |
Loading...